BeyondSpring Inc.
BYSI
NASDAQ·Healthcare·Biotechnology·Mkt cap $25.1M
$0.61
▲ +1.39%
P/E
-3.76
Mkt Cap
$25.1M
52-Wk Range
$0.57–$2.44
52-Week Range
$0.57 - $2.44
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 66.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary selective immune-modulating microtubule-binding technology
- Phase III clinical trial completion for lead candidate with strong efficacy data
- Strategic partnerships with leading immuno-oncology agents and major pharma
- Diversified pipeline addressing multiple high-incidence cancer indications
Bear Case
1 risk
- Low volatility (beta 0.4).
Growth
Turning profitable
Regulatory approval and commercialization of Plinabulin for FDA clearance
Value
Valuation data unavailable
Momentum
Falling
-64.9% over 3m
Quality
Loss-making
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying BYSI right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 12, 2026
AUG 14, 2026
Reported EPS of -$0.02 vs -$0.54 consensus (+96.3% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+96.3%
Revenue trend · last 8Q
—
—
-100%
-100%
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
-$1.0M
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
Gross
—
Operating
—
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How BYSI stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related